- Home
- IMMP vs CDRO Comparison
IMMP vs CDRO Comparison
Compare IMMP & CDRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMMP | CDRO |
|---|---|---|
| Founded | 1987 | 2014 |
| Country | Australia | Luxembourg |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Services-Misc. Amusement & Recreation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 410.7M | 363.1M |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | IMMP | CDRO |
|---|---|---|
| Price | $2.65 | $8.05 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $10.00 | $8.50 |
| AVG Volume (30 Days) | ★ 150.3K | 7.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $372.23 | $11.31 |
| Revenue Next Year | N/A | $7.51 |
| P/E Ratio | ★ N/A | $305.95 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.32 | $5.18 |
| 52 Week High | $3.53 | $8.75 |
Technical Indicators
Market Signals| Indicator | IMMP | CDRO |
|---|---|---|
| Relative Strength Index (RSI) | 43.35 | 57.55 |
| Support Level | $2.56 | $7.94 |
| Resistance Level | $2.71 | $8.24 |
| Average True Range (ATR) | 0.13 | 0.21 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 11.59 | 77.78 |
Price Performance
Historical ComparisonAbout IMMP Immutep Limited
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
About CDRO Codere Online Luxembourg S.A.
Codere Online Luxembourg SA is an international online casino gaming and online sports betting group focused on providing its customers with a safe and enjoyable online gaming experience. It currently operates in Spain, Mexico, Colombia, and Other countries. where it offers its users the ability to play online casino games and bet on sports events. Online casino offerings include the full portfolio of games typically available in land-based casinos, gaming halls and gambling establishments, such as slot machines, table games, and bingo. Online sports betting involves a user placing a wager on an event at some fixed odds determined by Codere Online. The company derives maximum revenue from Mexico.